Selective toxicity towards myelodysplastic hematopoietic progenitors - Another rationale for iron chelation in MDS

Leukemia Research

Volumn 36, Issue 8, 2012, Pages 962-963

  Fibach, E ^a   Rachmilewitz, E A ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; FERRITIN; GLUTATHIONE; IRON; REACTIVE OXYGEN METABOLITE;

CD4+ T LYMPHOCYTE; CELL VIABILITY; CLONE; CONCENTRATION RESPONSE; CULTURE MEDIUM; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; EDITORIAL; HEMATOPOIETIC STEM CELL; HUMAN; IRON OVERLOAD; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

BENZOIC ACIDS; CELL PROLIFERATION; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; REACTIVE OXYGEN SPECIES; TRIAZOLES;

EID: 84862527496     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.04.030     Document Type: Editorial

References (9)

1. Gattermann N., Rachmilewitz E.A. Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol 2011, 90:1-10.
2. Fibach E., Rachmilewitz E. The role of oxidative stress in hemolytic anemia. Curr Mol Med 2008, 8:609-619.
3. Ghoti H., Fibach E., Merkel D., Perez-Avraham G., Grisariu S., Rachmilewitz E.A. Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes. Haematologica 2010, 95:1433-1434.
4. Chee C.E., Steensma D.P., Wu W., Hanson C.A., Tefferi A. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol 2008, 83:611-613.
5. Rose C., Brechignac S., Vassilief D., Pascal L., Stamatoullas A., Guerci A., et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res 2010, 34:864-870.
6. Callens C., Coulon S., Naudin J., Radford-Weiss I., Boissel N., Raffoux E., et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med 2010, 207:731-750.
7. Cohen A.R., Galanello R., Piga A., De Sanctis V., Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003, 102:1583-1587.
8. Novotna B., Bagryantseva Y., Siskova M., Neuwirtova R. Oxidative DNA damage in bone marrow cells of patients with low-risk myelodysplastic syndrome. Leuk Res 2009, 33:340-343.
9. Penhallow R.C., Brown-Mason A., Woodworth R.C. Comparative studies of the binding and growth-supportive ability of mammalian transferrins in human cells. J Cell Physiol 1986, 128:251-260.